Wandering star disrupts stellar nursery

A young protostar in L483 and its signature outflow peeks out through a shroud of dust in this infrared image from NASA's Spitzer Space Telescope. Stars are known to form from collapsing clumps of gas and dust, or envelopes, seen here around a forming star system as a dark blob, or shadow, against a dusty background. The greenish color shows jets coming away from the young star within. The envelope is roughly 100 times the size of our solar system.
Credit: NASA/JPL-Caltech/J.Tobin University of Michigan

From a zoomed out, distant view, star-forming cloud L483 appears normal. But when a Northwestern University-led team of astrophysicists zoomed in closer and closer, things became weirder and weirder.

As the researchers peered closer into the cloud, they noticed that its magnetic field was curiously twisted. And then — as they examined a newborn star within the cloud — they spotted a hidden star, tucked behind it.

“It’s the star’s sibling, basically,” said Northwestern’s Erin Cox, who led the new study. “We think these stars formed far apart, and one moved closer to the other to form a binary. When the star traveled closer to its sibling, it shifted the dynamics of the cloud to twist its magnetic field.”

The new findings provide insight into binary star formation and how magnetic fields influence the earliest stages of developing stars.

Cox presented this research at the 240th meeting of the American Astronomical Society (AAS) in Pasadena, California. “The Twisted Magnetic Field of L483” will take place on Tuesday, June 14, as a part of a session on “Magnetic Fields and Galaxies.” The Astrophysical Journal will also publish the study next week.

Speed and dense gas bend jets of matter streaming away from some galaxy centers

Paired jets of matter streaming away from supermassive black holes at the center of galaxies usually extend away in opposite directions along the black hole’s axis of spin — as in the two bottom galaxy images. But some, like the two top galaxies, have jets bent at odd angles.
Credit: Melissa Morris, Uw–Madison

The most active and gluttonous black holes in the universe can often be found with two jets of matter streaming from their centers. These jets accelerate with astounding speed out into space in opposite directions, and they are usually lined up along the axis of the spinning black hole. But not always.

Some of these supermassive black galaxy hearts, called active galactic nuclei, have jets bent at mysteriously odd angles. New research from astronomers at the University of Wisconsin–Madison, published recently in The Astronomical Journal, shows that these jets are probably bent by a combination of their galaxies moving at tremendous velocity and by drag on the jets as they pass through clouds of intergalactic gas.

“These active galactic nuclei are a subset of black holes that are — even for black holes — really quickly gobbling up an enormous amount of matter,” says Melissa Morris, a UW–Madison astronomy graduate student and lead author of the new study. “They’re being fueled so quickly that a ton of energy is released in the area around the black hole. That’s what causes these wild AGN jets.”

Study Finds No Benefit to Taking Ivermectin for COVID-19 Symptoms

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between participants taking ivermectin and participants taking a placebo.

“There was no significant benefit in our primary endpoint of resolution of symptoms in mild-to-moderate COVID-19 illness,” said Adrian Hernandez, M.D., the study’s administrative principal investigator and executive director of the DCRI. “Overall, most people improved their symptoms whether they took ivermectin or not. Given these results, there does not appear to be a role for ivermectin outside of a clinical trial setting, especially considering other available options with proven reduction in hospitalizations and death.”

There was also no difference observed in the number of hospitalizations or emergency room visits. Findings appear on medRxiv, a pre-publication server, and have been submitted to a peer-reviewed journal.

ACTIV-6 -- “The Randomized Trial to Evaluate Efficacy of Repurposed Medications” -- is a nationwide double-blind study that has enrolled more than 4,000 participants. The trial continues to enroll with plans to include nearly 15,000 participants from across the United States.

Ivermectin, a medication used to treat parasitic infections, is one of three repurposed medications currently being tested in ACTIV-6. Repurposed medications are those already approved by the U.S. Food and Drug Administration (FDA) for other medical indications.

Good news on blocking a virus considered a global threat

Illustration of the Hendra virus

Scientists have reported good news on the pandemic preparedness front: A cocktail of four manufactured antibodies is effective at neutralizing a virus from the Henipavirus family, a group of pathogens considered to be a global biosecurity threat.

The study focused on protection against a recently identified variant of the Hendra virus, which, along with Nipah virus, has been responsible for deadly animal and human infection outbreaks in the Eastern Hemisphere. The 2011 movie Contagion depicts a fictional viral outbreak traced to an infected pig that is modeled on the Nipah virus.

The Hendra variant, identified in two fatally diseased horses and sick bats in Australia, featured dramatic genetic changes from the original virus – which created a sense of urgency among scientists to learn how existing countermeasures stack up against the restructured pathogen.

Researchers screened and determined in cell studies that several previously developed monoclonal antibodies designed to neutralize the original virus are also effective against the variant. The team also designed an additional antibody that could join three others in a powerful cocktail that would leave the virus with minimal ability to further mutate its way out of antibody recognition.

Lockheed Martin, KAI Sign Teaming Agreement for Future T-50 Opportunities

Aimee Burnett, Greg Ulmer and OJ Sanchez join Mr. Hyun-Ho Ahn, president & CEO, Korea Aerospace Industries, for the T-50 Teaming Agreement signing ceremony.
Credit: Lockheed Martin Corporation

Lockheed Martin and Korea Aerospace Industries (KAI) have signed a teaming agreement for future T-50 opportunities, the newest partnership in the decades-long relationship between the companies.

“Lockheed Martin is an air power solutions leader, delivering capabilities across the entire spectrum of training and combat aircraft,” says Aimee Burnett, vice president, Integrated Fighter Group Business Development at Lockheed Martin. “We are proud to continue to partner with KAI on the T-50 to leverage our collective experiences to train the next generation of pilots to fly, fight and win."

She says the T-50 is a proven aircraft program that reduces the learning curve for new pilots and gets them flying operational sorties faster – even in fifth-generation aircraft like the F-35. That’s important as air forces around the world need to get their pilots up to speed faster than ever before, whether that’s to fill a gap in personnel or due to increased frequency of combat missions.

“That’s where the benefits of the proven T-50 program really come into play,” she says. “The seamless training experience with the T-50 gives student pilots an additional edge and fully prepares them – in less time than in the past – to fly any combat mission.”

Researchers solve mystery surrounding dielectric properties of unique metal oxide

University of Minnesota Associate Professor Bharat Jalan and his students discovered that the true dielectric constant of their strontium titanate films exceeds 25,000—the highest ever measured for this material.
Credit: Jalan Group, University of Minnesota

A University of Minnesota Twin Cities-led research team has solved a longstanding mystery surrounding strontium titanate, an unusual metal oxide that can be an insulator, a semiconductor, or a metal. The research provides insight for future applications of this material to electronic devices and data storage.

The paper is published in the prestigious Proceedings of the National Academy of Sciences of the United States of America (PNAS), a peer-reviewed, multidisciplinary, scientific journal.

When an insulator like strontium titanateis placed between oppositely charged metal plates, the electric field between the plates causes the negatively charged electrons and the positive nuclei to line up in the direction of the field. This orderly lining up of electrons and nuclei is resisted by thermal vibrations, and the degree of order is measured by a fundamental quantity called the dielectric constant. At low temperature, where the thermal vibrations are weak, the dielectric constant is larger.

In semiconductors, the dielectric constant plays an important role by providing effective “screening,” or protection, of the conducting electrons from other charged defects in the material. For applications in electronic devices, it is critical to have a large dielectric constant.

A Fresh Take on Fat: Nanoparticle Technology Provides Healthy Trans, Saturated Fat Alternative

Yangchao Luo, an associate professor in the College of Agriculture, Health and Natural Resources.
 Credit: Jason Shelton/UConn Photo

The old adage that oil and water don’t mix isn’t entirely accurate. While it’s true that the two compounds don’t naturally combine, turning them into one final product can be done. You just need an emulsifier, an ingredient commonly used in the food industry.

Yangchao Luo, an associate professor in the College of Agriculture, Health and Natural Resources, is using an innovative emulsification process for the development of a healthier shelf-stable fat for food manufacturing.

Luo is working with something known as high internal phase Pickering emulsions (HIPEs). High internal phase means the mixture is at least 75% oil. Pickering emulsions are those that are stabilized by solid particles.

Previous research in Pickering emulsions has focused on non-edible particles, but Luo is interested in bringing HIPEs to the food industry as an alternative to trans and saturated fats.

This new approach could have a major impact on how food is produced and could make it easier for food manufacturers to include healthier fats.

Many processed foods are loaded with saturated and trans fats for flavor and to extend a product’s shelf life. Consuming these fats can increase the risk of cardiovascular disease, type 2 diabetes, and LDL cholesterol.

AI platform enables doctors to optimize personalized chemotherapy dose

Research team behind the PRECISE.CURATE trial (from left) Prof Dean Ho, Dr Agata Blasiak, Dr Raghav Sundar, Ms Anh Truong
Credit/Source: National University of Singapore

Based on a pilot clinical trial, close to 97% of dose recommendations by CURATE.AI were accepted by clinicians; some patients were prescribed optimal doses that were around 20% lower on average

A team of researchers from National University of Singapore (NUS), in collaboration with clinicians from the National University Cancer Institute, Singapore (NCIS) which is part of the National University Health System (NUHS), has reported promising results in using CURATE.AI, an artificial intelligence (AI) tool that identifies and better allows clinicians to make optimal and personalized doses of chemotherapy for patients.

Based on a pilot clinical trial – called PRECISE.CURATE - involving 10 patients in Singapore who were diagnosed with advanced solid tumors and predominantly metastatic colorectal cancers, clinicians accepted close to 97% of doses recommended by CURATE.AI, with some patients receiving optimal doses that were approximately 20% lower on average. These early outcomes are a promising step forward for the potential of truly personalizing oncology, where drug doses can be adjusted dynamically during treatment.

Developed by Professor Dean Ho and his team, CURATE.AI is an optimization platform that harnesses a patient’s clinical data, which includes drug type, drug dose and cancer biomarkers, to generate an individualized digital profile which is used to customize the optimal dose during the course of chemotherapy treatment.

Brain hereditary disease factor suspected

Jonasz Jeremiasz Weber, Rana Dilara Incebacak Eltemur, Priscila Pereira Sena, Huu Phuc Nguyen (from left) worked out the study together.
Credit: © Pengfei Qi

Similar to Alzheimer's, the hereditary disease Spinocerebellar Ataxia Type 17 (SCA17) leads to the demise of brain nerve cells and the premature death of those affected. The exact mechanisms of the disease are unknown, so there are no treatment approaches to date. Researchers of human genetics at the Ruhr University Bochum (RUB) around Dr. Jonasz Weber now suspects a class of protein-splitting enzymes, so-called calpaines, to contribute to the disease. In the model, the Calpaine was switched off to stop the course. The researchers report in the journal Cellular and Molecular Life Sciences.

Changed blueprint of a protein

Spinocerebellar ataxia type 17 (SCA17) is a rare, hereditary disease of the human brain. Due to the pathological change in a gene that contains the blueprint for a protein called TATA box-binding protein (TBP), the protein is formed in cells in a defective form. This also affects its function. "One consequence of this is that the protein forms detectable protein deposits in the brain and damages the nerve cells via molecular mechanisms that have not yet been fully elucidated," explains Jonasz Weber.

As a consequence, those affected by the disease develop symptoms such as movement disorders, seizures, impairment of mental performance as well as changes in nature and behavior, which are associated with the breakdown of tissues such as the cerebellum and brain stem.

IA leads the charge against multiple sclerosis

MRI image in false colors of a brain hemisphere from an MS patient (affected areas are shown in red).
 Credit: Govind Bhagavatheeshwaran, Daniel Reich / NINDS / NIH

Artificial intelligence may enable earlier diagnosis of Multiple Sclerosis, an incurable disease that attacks the central nervous system. This could improve the efficacy of treatments designed to slow its progression.

An autoimmune disease, multiple sclerosis (MS) is characterized by a breakdown of myelin, the membrane that protects the axons of neurons. Communication within the nervous system is gradually disrupted, causing increasingly severe motor and neurological damage. Although multiple sclerosis is currently incurable, treatments are available to relieve certain symptoms, particularly if the disease is discovered early; unfortunately, however, it tends to be diagnosed at a later stage.